ARTICLE | Financial News
BioMarin gains on analyst report
August 29, 2001 7:00 AM UTC
BMRN was up $1.49 (14%) to $12.49 on Wednesday after CIBC analyst Matt Geller began coverage with a "strong buy" and a $24 price target. Geller expects BMRN and partner Genzyme (GENZ) to launch Aldura...